The NCCN guidelines recommend JAK2 inhibitors or experimental therapy with consideration of early transplant for these MPN patients.8 With data reported for only 11 patients treated with ruxolitinib for MPN it is not possible to draw any conclusions regarding its effect on survival. This evidence concerns the gene JAK2 and myeloproliferative disorder.